News

Previously, Jeff Edelson worked as vice president, internal medicine and therapeutic area head – Novel Therapeutics in Johnson & Johnson. Dr Edelson prior industry experience includes leadership roles

The study, conducted in 16 healthy male subjects, was designed to explore the pharmacodynamic effects of a single oral dose of GLP-1 administered 15 minutes prior to an

Hemispherx is seeking marketing approval for the first-ever treatment for chronic fatigue syndrome (CFS). At present, only supportive, symptom-based care is available for CFS patients. The new drug

Franck Grimaud, CEO of Vivalis, said: “Vivalis is pleased to enter in this agreement to support Acambis’s R&D efforts for the development of new vaccines. “With already more

Bio-Bridge Science has one month to close the transaction, and obtain the new business license. The transaction is expected to close before the end of July 2008. Liang

This trial was designed to evaluate safety parameters for glycopyrrolate over a six-month period. Larry Dillaha, chief medical officer of Sciele Pharma, said: “We are excited to have

Heilongjiang Tianlong Pharmaceutical, a wholly-owned subsidiary of China Sky One Medical, has recently completed R&D for eight different types of injections, obtaining production approval for three injections, including

Bayer HealthCare’s Eovist is a paramagnetic MRI contrast agent that combines features of both an extracellular contrast agent and a hepatocyte-specific agent. The approval makes Eovist the first

Invitrogen’s Spot-Light Her2 CISH kit is based on a technology called chromogenic in situ hybridization (CISH). The test uses a DNA probe for the Her2 gene, which is